Thus, DHA-FFAR4 signaling is considered an impactful mechanism that suppresses bone resorption and stimulates bone formation, making FFAR4 an attractive therapeutic target in bone metabolic disorders such as osteoporosis, rheumatoid arthritis, and inflammatory osteolysis [41]. Here, FFAR4 is linked to metabolic bone disorder.